The recent approval enables Zydus Lifesciences to produce and sell Apalutamide Tablets, 60 mg (a generic equivalent of Erleada) in the United States. Apalutamide is an androgen receptor inhibitor ...

Stock Market Focus IndusInd Bank, Zydus, Dr. Reddy’s, More Zee Business Video Team | Updated: March 19, 2025 10:24 AM IST Which stocks will be in focus today including Indusind Bank, Zydus ...

The Board has extended Rajivnayan Rahulkumar Bajaj's tenure as Managing Director and Chief Executive Officer for another five years, starting April 1. Additionally, Abhinav Bindra has been ...

Zydus Lifesciences Limited announced on Tuesday that it has secured the final approval from the United States Food and Drug Administration (USFDA) for manufacturing and marketing apalutamide ...

Ahmedabad: Pharma major, Zydus Lifesciences Limited, has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, ...

Zydus Lifesciences Ltd. has received final nod from the United States Food and Drug Administration to manufacture 60 mg Apalutamide tablets, according to an exchange filing on Tuesday. Apalutamide is ...

Drug maker Zydus Lifesciences Ltd on Tuesday (March 18) said it has received the final approval from the United States Food and Drug Administration (FDA) to manufacture and market apalutamide tablets, ...

Zydus Lifesciences: The drug maker has received final approval from the US FDA to manufacture Apalutamide tablets in a 60 mg strength. (DISCLAIMER: The views and opinions expressed by investment ...

Zydus Lifesciences Ltd has received USFDA approval to manufacture a generic version of Apalutamide tablets for prostate cancer treatment. The 60 mg tablets will be produced in Ahmedabad, addressing a ...

We describe pronounced hypotension in a patient during orthostatic testing while receiving treatment with sildenafil and tamsulosin, but not with placebo. The patient was 71 years of age and had ...

Zydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 mg & 100 mg) for IBS-D treatment. The company secured 180 days of shared ...

The companies behind the product pulls are Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, all three of which hail from India. The drugmakers are recalling seizure treatments ...